Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal

Year.

Teva Pharmaceutical Industries Limited ("Teva" or the "Company") held its Annual
Meeting on June 23, 2022 (the "Annual Meeting"). At the Annual Meeting, Teva's
shareholders approved an amendment to the Company's Articles of Association (the
"Articles"), effective upon approval on June 23, 2022, to, among other things,
(i) eliminate the requirement for a minimum number of in-person meetings of the
Company's Board of Directors (the "Board"), (ii) provide the Chairman of the
Company's Board with discretion to determine, with respect to each year, whether
a majority of the in-person meetings of the Board shall be convened in Israel,
(iii) provide that the CEO shall lead the management team and manage the Company
from its headquarters in Israel, (iv) stipulate that the English language
version of the Articles shall be the binding version, (v) clarify that the Board
shall set the maximum number of directors to be appointed at each general
meeting, (vi) amend or remove certain additional provisions that either are
obsolete or no longer desirable due to changes in Teva's governance structure or
amendments to the Israeli Companies Law, 5759-1999, (vii) address Teva's unique
status as a company subject to both applicable Israeli and U.S. laws, rules and
regulations and (viii) correct minor ambiguities.

The foregoing description is qualified in its entirety by reference to the full
text of the amended Articles of Association which is attached hereto as Exhibit
3.1

Item 5.07 Submission of Matters to a Vote of Security Holders.

As described above, Teva held its Annual Meeting on June 23, 2022. The following is a summary of the matters voted on at the meeting.

(1) The shareholders elected to appoint the following persons to the Board, each to serve until Teva's 2025 annual meeting of shareholders, as follows:



Directors                For         Against     Abstain   Brokers non-vote

Amir Elstein 444,521,760 139,011,657 602,002 110,547,422 Roberto A. Mignone 469,539,322 113,977,054 619,040 110,547,425 Dr. Perry D. Nisen 473,460,959 110,070,839 603,618 110,547,425 Dr. Tal Zaks 475,714,380 107,826,034 595,006 110,547,421

(2) The shareholders approved, on a non-binding advisory basis, the compensation for Teva's named executive officers listed in the proxy statement for the Annual Meeting, as follows:

For Against Abstain Brokers non-vote 424,554,002 137,783,772 21,797,642 110,547,425




(3)  The shareholders approved Teva's Compensation Policy with respect to the
terms of office and employment of Teva's Executive Officers and Directors as
follows.

                                              For          Against

Abstain Brokers non-vote Indicating "YES" for personal interest 9,100,277 2,142,511 120,718

             0
Indicating "NO" for personal interest     415,051,270    126,286,322    21,564,100           0
Total                                     424,151,547    128,428,833    21,684,818           0

(4) The shareholders approved amendments to Teva's Articles, as follows:

For Against Abstain Brokers non-vote 523,934,723 58,788,742 1,411,956 110,547,420

--------------------------------------------------------------------------------

(5) The shareholders approved the appointment of Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva's independent registered public accounting firm until Teva's 2023 annual meeting of shareholders, as follows:



    For        Against      Abstain    Brokers non-vote
667,890,796   21,659,403   1,296,846          0

Item 9.01 Financial Statements and Exhibits




(d) Exhibits.

Exhibit No.       Description of Document

3.1                 Articles of Association

104               Cover Page Interactive Data File (embedded within the Inline XBRL
                  document)



                                       3

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses